二者关系疏于监管,可谓一团糟。一个(有益的)极端是,企业为创造新的治疗方案与医生合作。另一个极端则是企业向医生行贿,以便让医生在开药时选择他们厂家的产品。美国司法部门从此类官司涉及的公司中榨取了大量罚金。两个极端之间可以有种种行事,有些人视之为标准,有些人则嗤之以鼻,而新法律对这些管得越来越严了。
This month American regulators released rules to implement a so-called Sunshine law designed to improve transparency. France passed a similar law in 2011. Firms in Britain are planning voluntary disclosures. By 2017 more than 70% of drug sales will be in countries with such measures, according to Deloitte, a consultancy.
本月,美国监管机构公布了新规定,旨在贯彻实施一部所谓的“阳光法案”,以提高企业透明度。法国在2011年通过了一部类似的法案。英国的企业正计划着主动公示信息。据咨询公司德勤(Deloitte)显示,在2017年前,70%以上的药品会在采取此类措施的国家中销售。
America’s health-care market, the world’s biggest, is particularly busy. In 2017 pharmaceutical companies spent more than $24 billion marketing drugs to doctors, according to Cegedim Strategic Data, a research firm; 35% of doctors accept food, entertainment or travel from the pharmaceutical industry, said a survey by Deloitte last year, while 16% accept consulting or speaking fees. In most states, doctors take regular courses to maintain their licences. In 2011 drug and device companies sponsored nearly a third of the medical training tracked by the Accreditation Council for Continuing Medical Education.
【揭露药医利益关系的新招】相关文章:
★ 雪碧换包装了
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15